Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.7990
-0.0063 (-0.78%)
At close: Jun 26, 2025, 4:00 PM
0.8107
+0.0117 (1.46%)
After-hours: Jun 26, 2025, 6:13 PM EDT
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 7 analysts that cover Sutro Biopharma stock have a consensus rating of "Hold" and an average price target of $3.97, which forecasts a 396.87% increase in the stock price over the next year. The lowest target is $0.8 and the highest is $15.
Price Target: $3.97 (+396.87%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sutro Biopharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $2 | Hold → Buy | Upgrades | $2 | +150.31% | Jun 16, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $1 → $0.8 | Sell | Maintains | $1 → $0.8 | +0.13% | May 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $2 | Hold | Reiterates | $2 | +150.31% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $12 → $2 | Strong Buy → Hold | Downgrades | $12 → $2 | +150.31% | Mar 17, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 14, 2025 |
Financial Forecast
Revenue This Year
60.02M
from 62.04M
Decreased by -3.26%
Revenue Next Year
45.71M
from 60.02M
Decreased by -23.84%
EPS This Year
-1.91
from -2.96
EPS Next Year
-1.24
from -1.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.7M | 72.2M | 72.2M | ||
| Avg | 60.0M | 45.7M | 43.9M | ||
| Low | 16.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.5% | 20.2% | 58.0% | ||
| Avg | -3.3% | -23.8% | -3.9% | ||
| Low | -73.1% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.12 | -0.55 | -0.93 |
| Avg | -1.91 | -1.24 | -1.57 |
| Low | -2.81 | -2.29 | -2.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.